Karron has been working with colleagues at the National Institutes of Health on one of several efforts to develop a vaccine. She said she hopes it will be available within the next five to 10 years. A vaccine given to pregnant mothers to protect their babies could be ready sooner. The virus doesn’t evolve much, Karron said, so unlike the flu, which adapts frequently, a vaccine would not have to be updated from year to year.
Dr. Anna P. Durbin presents: The Dengue Human Infection Model: A Critical Tool for Development of a Safe and Effective Vaccine. The lecture will be presented on February 13, 2019 as part of the Johns Hopkins School of Public Health Dean’s Lecture series. Dr. Durbin is an expert in flavivirus vaccine research, leading CIR’s Team FIRE […]
As the world prepares to fight Lassa fever, the interests of pregnant women must be part of the planning
In a First Opinion piece published by STAT News, members of the Pregnancy Research Ethics for Vaccines Epidemics, and New Technologies (PREVENT) working group, including CIR Director Dr. Ruth Karron, speak candidly about the re-emergence of Lassa Fever and it’s potential impact on pregnant and lactating women in affected communities.
Historically, pregnant women have been excluded as potential investigational vaccine recipients during outbreaks, because there is little or no safety data for the unborn fetus. However, the multidisciplinary group of experts that compose PREVENT have re-evaluated the automatic exclusion of pregnant women from vaccine clinical research trials and from the receipt of vaccines in the event of outbreaks like the recent Ebola outbreak in the Congo.
Dr. Karron discussed the importance of a licensed RSV vaccine in an interview with WMAR2News reporter Ashley James. “In young children, the virus can spread to the lungs and cause pneumonia or wheezing, dangerous wheezing illness. That’s what makes them so sick. And in very young children RSV can actually cause infants to stop breathing.”
Researchers investigated the feasibility of maternal RSV vaccine trials to demonstrate reductions in recurrent childhood wheezing in general pediatric populations.
What is the current landscape for dengue, zika and other arbovirus vaccines? Which other arboviruses should be prioritized for vaccine development or for improvements of the existing vaccine(s)? How will the immune response to one virus affect that of another? What are the challenges to funding and commercializing arbovirus vaccines?
Days after the Democratic Republic of the Congo declared an end to a deadly Ebola outbreak in the western province of Équateur, a new one emerged in North Kivu province. With the number of cases and death toll rising rapidly, the country’s ministry of health, the World Health Organization, and partners are working to launch a rapid and effective response that includes the use of an experimental vaccine. But their decision not to vaccinate women who are pregnant or lactating unfairly deprives them of the protection they deserve against this deadly disease.